| HLINOMAZ, Ota, Zuzana MOTOVSKA, Jiri KNOT, Roman MIKLÍK, Mulham SABBAH, Milan HROMADKA, Ivo VARVAROVSKY, Jaroslav DUSEK, Michal SVOBODA, Frantisek TOUSEK, Bohumil MAJTAN, Stanislav SIMEK, Marian BRANNY and Jiří JARKOVSKÝ. Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial. Journal of Clinical Medicine. Basel: MDPI, 2021, vol. 10, No 21, p. 1-12. ISSN 2077-0383. Available from: https://dx.doi.org/10.3390/jcm10215103. |
Other formats:
BibTeX
LaTeX
RIS
@article{1807765,
author = {Hlinomaz, Ota and Motovska, Zuzana and Knot, Jiri and Miklík, Roman and Sabbah, Mulham and Hromadka, Milan and Varvarovsky, Ivo and Dusek, Jaroslav and Svoboda, Michal and Tousek, Frantisek and Majtan, Bohumil and Simek, Stanislav and Branny, Marian and Jarkovský, Jiří},
article_location = {Basel},
article_number = {21},
doi = {http://dx.doi.org/10.3390/jcm10215103},
keywords = {acute myocardial infarction; primary angioplasty; drug-eluting stent; bare-metal stent; bioresorbable scaffolds; ticagrelor; prasugrel},
language = {eng},
issn = {2077-0383},
journal = {Journal of Clinical Medicine},
title = {Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial},
url = {https://www.mdpi.com/2077-0383/10/21/5103},
volume = {10},
year = {2021}
}
TY - JOUR ID - 1807765 AU - Hlinomaz, Ota - Motovska, Zuzana - Knot, Jiri - Miklík, Roman - Sabbah, Mulham - Hromadka, Milan - Varvarovsky, Ivo - Dusek, Jaroslav - Svoboda, Michal - Tousek, Frantisek - Majtan, Bohumil - Simek, Stanislav - Branny, Marian - Jarkovský, Jiří PY - 2021 TI - Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial JF - Journal of Clinical Medicine VL - 10 IS - 21 SP - 1-12 EP - 1-12 PB - MDPI SN - 20770383 KW - acute myocardial infarction KW - primary angioplasty KW - drug-eluting stent KW - bare-metal stent KW - bioresorbable scaffolds KW - ticagrelor KW - prasugrel UR - https://www.mdpi.com/2077-0383/10/21/5103 N2 - Drug-eluting stents (DES) are the recommended stents for primary percutaneous coronary intervention (PCI). This study aimed to determine why interventional cardiologists used non-DES and how it influenced patient prognoses. The efficacy and safety outcomes of the different stents were also compared in patients treated with either prasugrel or ticagrelor. Of the PRAGUE-18 study patients, 749 (67.4%) were treated with DES, 296 (26.6%) with bare-metal stents (BMS), and 66 (5.9%) with bioabsorbable vascular scaffold/stents (BVS) between 2013 and 2016. Cardiogenic shock at presentation, left main coronary artery disease, especially as the culprit lesion, and right coronary artery stenosis were the reasons for selecting a BMS. The incidence of the primary composite net-clinical endpoint (EP) (death, nonfatal myocardial infarction, stroke, serious bleeding, or revascularization) at seven days was 2.5% vs. 6.3% and 3.0% in the DES, vs. with BMS and BVS, respectively (HR 2.7; 95% CI 1.419-5.15, p = 0.002 for BMS vs. DES and 1.25 (0.29-5.39) p = 0.76 for BVS vs. DES). Patients with BMS were at higher risk of death at 30 days (HR 2.20; 95% CI 1.01-4.76; for BMS vs. DES, p = 0.045) and at one year (HR 2.1; 95% CI 1.19-3.69; p = 0.01); they also had a higher composite of cardiac death, reinfarction, and stroke (HR 1.66; 95% CI 1.0-2.74; p = 0.047) at one year. BMS were associated with a significantly higher rate of primary EP whether treated with prasugrel or ticagrelor. In conclusion, patients with the highest initial risk profile were preferably treated with BMS over BVS. BMS were associated with a significantly higher rate of cardiovascular events whether treated with prasugrel or ticagrelor.
ER - HLINOMAZ, Ota, Zuzana MOTOVSKA, Jiri KNOT, Roman MIKLÍK, Mulham SABBAH, Milan HROMADKA, Ivo VARVAROVSKY, Jaroslav DUSEK, Michal SVOBODA, Frantisek TOUSEK, Bohumil MAJTAN, Stanislav SIMEK, Marian BRANNY and Jiří JARKOVSKÝ. Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial. \textit{Journal of Clinical Medicine}. Basel: MDPI, 2021, vol.~10, No~21, p.~1-12. ISSN~2077-0383. Available from: https://dx.doi.org/10.3390/jcm10215103.
|
